NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
With reference to company announcements no. 2/2017 dated 6 November 2017 and no. 5/2017 dated 16 November 2017, Orphazyme A/S ("Orphazyme") today announces that it has received confirmation from the Joint Global Coordinators, on behalf of the managers, acting as underwriters that none of the termination rights of the underwriters provided for in the underwriting agreement dated 6 November 2017 have been invoked. The Initial Public Offering (the "IPO") and admission to trading and official listing of Orphazyme on Nasdaq Copenhagen A/S ("Nasdaq Copenhagen") will therefore not be terminated or withdrawn.
Subject to the registration of the new shares subscribed for in connection with the IPO with the Danish Business Authority, the IPO is considered completed with the admission to trading and official listing on Nasdaq Copenhagen becoming unconditional. A separate company announcement will be published in this regard.
Carnegie and Danske Bank are acting as Joint Global Coordinators and Joint Bookrunners, and Oddo BHF SCA is acting as Co-Lead Manager for the IPO.
For additional information, please contact
Anders Hinsby, CEO +45 31 44 31 39